1xbet 신청., Ltd.

• Below is a summary English translation provided by 1xbet 신청 as a reference. The original and full press release in Japanese was issued by Takeda and 1xbet 신청 on March 25.

1xbet 신청., Ltd. (Otsuka) and Takeda Pharmaceutical Co., Ltd. (Takeda) announce that approval has been granted by Japan's Ministry of Health, Labor and Welfare for Cabpirin_®Combination Tablets, a combination of the potassium-competitive acid blocker (P-CAB) vonoprazan fumarate and low-dose aspirin that will be co-promoted in Japan by 1xbet 신청 and Takeda. Cabpirin was created by Takeda, which will manufacture it.

Cabpir1xbet 신청_®Comb1xbet 신청ation Tablets is a once-daily oral formulation conta1xbet 신청1xbet 신청g 100 mg of aspir1xbet 신청 and 10 mg of vonoprazan 1xbet 신청 one tablet. By comb1xbet 신청1xbet 신청g low-dose aspir1xbet 신청 with vonoprazan, it is expected that adherence may be improved 1xbet 신청 patients who need to take both, and that the recurrence of gastric and duodenal ulcers, which are potential side effects of the adm1xbet 신청istration of low-dose aspir1xbet 신청, may be reduced.